Compass Pathways Plc
Compass Pathways Plc (CMPS) is a clinical‑stage mental health company developing COMP360, a psilocybin‑assisted therapy aimed primarily at treatment‑resistant depression. The firm is pursuing regulatory approvals and larger clinical trials while also building manufacturing, training and delivery capabilities needed for a regulated therapeutic model. With a market capitalisation of about $624 million, Compass is not yet a commercial biopharma — its value largely reflects clinical progress, regulatory milestones and investor expectations. That profile can mean above‑average volatility and financing needs as trials advance. Investors often watch trial results, regulatory guidance, partnerships and balance‑sheet health. Given the experimental nature of psychedelic therapies and the early stage of Compass’s programmes, this stock suits investors willing to accept substantial risk and a long time horizon. This information is educational, not personal financial advice; outcomes can vary and past performance does not predict future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Compass Pathways' stock with a target price of $16.82, indicating growth potential.
Financial Health
Compass Pathways is showing strong cash flow and a reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CMPS
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketEmployee Mental Health As A Benefit
Discover companies transforming workplace wellness through innovative mental health solutions. These carefully selected stocks represent businesses helping corporations attract and retain talent by offering digital therapy, virtual counseling, and wellness technologies as employee benefits.
Published: June 17, 2025
Explore BasketMental Wellness Portfolio
Invest in the future of mental healthcare. These carefully selected companies are leveraging technology to make mental health treatment more accessible, personalized, and effective, creating significant growth opportunities in an expanding market.
Published: June 17, 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical progress focus
Investors watch trial readouts and regulatory guidance as key value drivers, though outcomes and timelines can change.
High‑risk, high‑volatility
As an experimental therapy developer, Compass can see sharp share moves and may require further funding; suitable for risk‑tolerant investors.
Therapy delivery system
Beyond drugs, Compass is building training and manufacturing pathways — important for eventual commercialisation, with operational risks to manage.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
